Showing results (51-60 of 62) with videos related to
Sort By:
Pageof 7
Cell Death and Differentiation|December 26, 2025
Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanismsMaria Davern, Cole J Turner, Daryl Griffin, et al.Biorxiv : the Preprint Server for Biology|February 6, 2026
Extracellular vesicles facilitate the horizontal transfer of drug resistance and stem-like properties between ovarian tumor cellsVenkatesh Pooladanda, Rui Xu, Dominique T Zarrella, et al.Science (New York, N.Y.)|October 29, 2011
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapyTriona Ni Chonghaile, Kristopher A Sarosiek, Thanh-Trang Vo, et al.Cancer Discovery|May 2, 2019
Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating AgentsChen Lossos, Yunpeng Liu, Kellie E Kolb, et al.Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.Molecular Cancer Research : MCR|August 30, 2019
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian CancerElizabeth H Stover, Maria B Baco, Ofir Cohen, et al.Cell|September 18, 2018
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in GliomaSamuel K McBrayer, Jared R Mayers, Gabriel J DiNatale, et al.Science Advances|August 19, 2021
Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severityZintis Inde, Ben A Croker, Clarence Yapp, et al.Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.Science Translational Medicine|February 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastomaVeronica Rendo, Eudocia Q Lee, Connor Bossi, et al.Pageof 7